89 activities found

Investigator Insights: New Directions in Targeting Angiogenesis for Metastatic Colorectal Cancer

In the third e-learning activity of this 4-part series, Richard M. Goldberg, MD and Paul Ruff, MD discuss the key clinical study data presented at the 2015 annual meeting of the American Society for Clinical Oncology (ASCO) pertaining to the use of angiogenesis inhibitors in metastatic colorectal cancer (mCRC). These experts highlight the clinical outcomes of these trial with special attention on trial design and characteristics and eligibility criteria of enrolled subjects. They identify clinical situations in which evidence is robust and others in which more data are needed to better help direct clinical decision making.
0.75 CME

Webcast: IBD Pathogenesis: Personalizing Targets

Recent scientific discoveries regarding the pathobiology of IBD and the number of new and emerging therapies recently approved and in late phase development necessitate education for nurses to enhance their ability to provide personalized care to patients with IBD. This educational activity repeats the session IBD Pathogenesis: Personalizing Targets presented by Laryl Riley, RNP during the satellite symposium Therapeutic Management of IBD: The Paradigm Shift to Personalized Care during the national gastroenterology nursing conference in Baltimore, Maryland, May 16, 2015.
0.5 CNE

Webcast: Personalized Medicine: Right Drug for the Right Patient

Recent scientific discoveries regarding the pathobiology of IBD and the number of new and emerging therapies recently approved and in late phase development necessitate education for nurses to enhance their ability to provide personalized care to patients with IBD. This educational activity repeats the session Personalized Medicine: The Right Drug for the Right Patient presented by Michele Rubin, APN, MSN, CNS, CGRN during the satellite symposium Therapeutic Management of IBD: The Paradigm Shift to Personalized Care during the national gastroenterology nursing conference in Baltimore, Maryland, May 16, 2015.
0.5 CNE

Webcast: Addressing Risks and Benefits of IBD Therapy: The Balancing Act

Recent scientific discoveries regarding the pathobiology of IBD and the number of new and emerging therapies recently approved and in late phase development necessitate education for nurses to enhance their ability to provide personalized care to patients with IBD. This educational activity repeats the session Addressing Risks and Benefits of IBD Therapy: The Balancing Act presented by Maureen Kelly, RN, MS, CPNP during the satellite symposium Therapeutic Management of IBD: The Paradigm Shift to Personalized Care during the national gastroenterology nursing conference in Baltimore, Maryland, May 16, 2015.
0.5 CNE

Webcast: Evolving Paradigms in Castration-Resistant Prostate Cancer: An Online Interactive Opinion Leader Workshop

In the past 4 years, our increased understanding of prostate cancer biology and mechanisms of tumor resistance have led to a number of clinical trials using new therapeutic agents, resulting in several new FDA approvals. Additionally, new agents are currently under clinical investigation in continuous efforts to improve the efficacy and safety of Castration-Resistant Prostate Cancer (CRPC) treatment. The introduction of these novel therapeutic agents, however, requires physicians to make complicated decisions regarding treatment protocols for their patients with CRPC. Questions of agent selection, treatment sequencing methods, combination treatment strategies, and individualized therapeutic approaches for newly approved and emerging CRPC drugs remain unanswered. This activity aims to address these challenges through an interactive online opinion leader workshop with 3 experts in the field of prostate cancer discussing the clinical data regarding available and investigational agents and the most effective ways to utilize those agents for long-term disease control.
1.5 CME

Expert Perspectives: The Clinical Potential of PARP Inhibitors in Ovarian Cancer

In this Expert Perspectives™ activity, Dr. Bradley Monk leads a conversation with Dr. Ursula Matulonis and Dr. Thomas Herzog, on the clinical potential of novel PARP inhibitors for improved management of epithelial ovarian cancer. This discussion is a review of their symposium presented during the 2015 Annual Conference of ASCO.
0.5 CME

Expert Perspectives: Best Practices and Emerging Treatment Strategies in the Management of Chemotherapy-Induced Nausea and Vomiting

Expert Perspectives™: Best Practices and Emerging Treatment Strategies in the Management of Chemotherapy-Induced Nausea and Vomiting will evaluate the rapid evolution of therapeutic options and practice guidelines in supportive care, including management of chemotherapy-induced nausea and vomiting (CINV) that can potentially change the way patients are treated on a continual basis.
0.75 CME

Webcast: Treatment Strategies for the Polycythemia Vera Patient

This roundtable discussion, Treatment Strategies for the Polycythemia Vera Patient, features a conversation between the moderator, Dr. Srdan Verstovsek, and faculty experts, Drs. Carlos Besses, Claire Harrison, and Francesco Passamonti, highlighting the evidence-based diagnosis, therapy and management of patients with polycythemia vera. Additionally, the expert panel provides an assessment of pertinent clinical studies, to offer recommendations and guidance for optimizing clinical outcomes to facilitate the improvement of patient quality of life.
0 CME

Expert Perspectives: Evolution of Personalized IBD Care: Navigating Mechanisms of Biologic Therapies

Expert Perspectives™: The Evolution of Personalized IBD Care: Navigating Mechanisms of Biologic Therapies will evaluate pathophysiologic mechanisms underlying these diseases as a foundation for appropriate implementation of current and emerging therapies. The recommended education will begin with elucidating the role of inflammatory pathways involved in the pathogenesis of IBD, then evaluate agents designed to inhibit their deleterious effects, evaluate safety and efficacy data reported to date, personalize treatment strategies, and assess potential clinical applications. Shared decision making will be addressed in this educational initiative and is a pivotal component of clinical practice that leads to therapeutically advantageous outcomes. The overall goal of this clinical encounter is to establish trust, provide education, encourage patient follow-up and compliance and provide supportive strategies for patients dealing with acute and chronic diseases.
0.75 CME

Best of the Day: ASCO 2015 Update to the 16th European Congress

This Best of the Day activity serves to provide a brief synopsis of the key points presented on thoracic oncology at the 2015 ASCO Annual Meeting held in Chicago, Illinois. Dr. Giorgio V. Scagliotti and Dr. Pieter Postmus discuss clinical updates for the therapy and management of patients with lung cancer. This expert review and conversation covers recent developments in molecular targets, the advent of immunotherapy, and management strategies for patients with early and advanced stage lung cancer.